This is a working overview of Melanotan II, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-25. Anything still debated is marked as such rather than presented as settled.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
== Partial list of peptide hormones in humans == Adrenocorticotropic hormone (ACTH) Adropin Amylin Angiotensin Atrial natriuretic peptide (ANP) Calcitonin Cholecystokinin (CCK) Gastrin Ghrelin Glucagon Glucose-dependent insulinotropic polypeptide (GIP) Glucagon-like peptide-1 (GLP-1) Growth hormone Follicle-stimulating hormone (FSH) Human chorionic gonadotropin (hCG) Insulin Leptin Luteinizing hormone (LH) Melanocyte-stimulating hormone (MSH) Orexin/Hypocretin Oxytocin Parathyroid hormone (PTH) Prolactin Renin Somatostatin Thyroid-stimulating hormone (TSH) Thyrotropin-releasing hormone (TRH) Vasopressin, also called arginine vasopressin (AVP) or anti-diuretic hormone (ADH) Vasoactive intestinal peptide (VIP) Somatotropin (GH1) Gonadotropin Releasing Hormone 1 (GNRH1) Gonadotropin Releasing Hormone 2 (GNRH2) Growth Hormone Releasing Hormone (GHRH) Parathyroid Hormone Like Hormone (PTHLH) Corticotropin Releasing Hormone (CRH) Anti-Müllerian Hormone (AMH) Chorionic Somatomammotropin Hormone 1 (CSH1) Chorionic Somatomammotropin Hormone 2 (CSH2) Pro-Melanin Concentrating Hormone (PMCH) Resistin (RETN)
Between 2007 and 2012, Mexico's National Human Rights Commission received nearly 5,800 complaints of military abuse and issued around 90 detailed reports documenting violations against civilians committed while the armed forces carried out policing duties. The Mexican military operated with minimal accountability for abuses committed in its campaigns.
== History == The term operando first appeared in catalytic literature in 2002. It was coined by Miguel A. Bañares, who sought to name the methodology in a way that captured the idea of observing a functional material – in this case a catalyst – under actual working, i.e. device operation, conditions. The first international congress on operando spectroscopy took place in Lunteren, Netherlands, in March 2003, followed by further conferences in 2006 (Toledo, Spain), 2009 (Rostock, Germany), 2012 (Brookhaven, USA), and 2015 (Deauville, France). The name change from in situ to operando for the research field of spectroscopy of catalysts under working conditions was proposed at the Lunteren congress. The analytical principle of measuring the structure, property and function of a material, a component disassembled or as part of a device simultaneously under operation conditions is not restricted to catalysis and catalysts. Batteries and fuel cells have been subject to operando studies with respect to their electrochemical function.
Sources: en.wikipedia.org
Australia: Electronic Travel Authority (ETA) eVisitor programme East African Community: From February 2014, Kenya, Rwanda and Uganda issue an East African Tourist Visa. Hong Kong: Mainland Travel Permit for Taiwan Residents India: India permits nationals of most jurisdictions to clear border controls using an e-visa. Kenya: From 1 January 2021, Kenya solely issues e-visas, and physical visas are no longer available. New Zealand: Electronic Travel Authority (NZeTA) North America: Canadian ETA, US Electronic System for Travel Authorisation Pakistan: Pakistani ETA. South Korea: eligible visa-free visitors must obtain Korea Electronic Travel Authorization (K-ETA). Sri Lanka: Sri Lankan ETA Qatar: ETA needed for up to 30 days. United Kingdom: Electronic Visa Waiver, or EVW The Nationality and Borders Bill, before the parliament in Spring 2022, includes a proposal to introduce the Electronic Travel Authorisation system for all non-UK and Irish citizens.
phosphate backbone Also phosphodiester backbone, sugar–phosphate backbone, and phosphate–sugar backbone. The linear chain of alternating phosphate and sugar compounds that results from the linking of consecutive nucleotides in the same strand of a nucleic acid molecule, and which serves as the structural framework of the nucleic acid. Each individual strand is held together by a repeating series of phosphodiester bonds connecting each phosphate group to the ribose or deoxyribose sugars of two adjacent nucleotides. These bonds are created by ligases and broken by nucleases.
Magnetohydrodynamics (MHD; also called magnetofluid dynamics or hydromagnetics) is a model of electrically conducting fluids that treats all types of charged particles together as a single continuous fluid. It is primarily concerned with the low-frequency, large-scale magnetic behavior of plasmas and liquid metals and has applications in multiple fields, including space physics, geophysics, astrophysics, and engineering.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.